Liver fat accumulation in inflammatory bowel disease

Liver fat accumulation in inflammatory bowel disease - IBD and fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44598

Enrollment

100

Registered

2017-05-30

Start date

2017-06-01

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic bowel inflammation inflammatory bowel disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient age >18 years A confirmed diagnosis of either crohns disease, ulcerative colitis or IBD-unclassified.

Exclusion criteria

Exclusion criteria: Patients unable or unwilling to provide informed consent

Design outcomes

Primary

Measure	Time frame
Primary outcome measure will be CAP en Emed (Fibroscan measures for steatosis grade and fibrosis respectively)	—

Secondary

Measure	Time frame
Secondary study parameters: are to compare the relation between the following parameters and liver steatosis/ fibrosis: 1. Mediterranean Diet Serving Scale, as a measure of healthy food intake. 2. Food related quality of life (FR-QoL), disease-specific quality of life (sIBDQ) and general quality of life (SF-12) 3. Clinical activity of IBD (as assessed using symptom scores (Harvey-Bradshaw index (HBI) for CD activity and the MAYO score for UC activity), CRP and fecal calprotectin (the latter , as part of standard medical care) 4. Nutritional status and anthropometry (body weight, hand grip strength, waist-hip ratio) 5. Medication use 6. In patients with active disease at baseline, accumulation of liver fat will be compared between different types of medication used (steroids- mesalamine compounds- immune-modulators and biologicals)	—

Measure

Time frame

Secondary study parameters: are to compare the relation between the following parameters and liver steatosis/ fibrosis: 1. Mediterranean Diet Serving Scale, as a measure of healthy food intake. 2. Food related quality of life (FR-QoL), disease-specific quality of life (sIBDQ) and general quality of life (SF-12) 3. Clinical activity of IBD (as assessed using symptom scores (Harvey-Bradshaw index (HBI) for CD activity and the MAYO score for UC activity), CRP and fecal calprotectin (the latter , as part of standard medical care) 4. Nutritional status and anthropometry (body weight, hand grip strength, waist-hip ratio) 5. Medication use 6. In patients with active disease at baseline, accumulation of liver fat will be compared between different types of medication used (steroids- mesalamine compounds- immune-modulators and biologicals)

—

Countries

Netherlands

Outcome results